open access

Vol 17, No 6 (2012)
Original research articles
Published online: 2012-11-01
Submitted: 2011-01-13
Get Citation

Comparison of neoadjuvant oral chemotherapy with UFT plus Folinic acid or Capecitabine concomitant with radiotherapy on locally advanced rectal cancer

Sofia Conde, Margarida Borrego, Tânia Teixeira, Rubina Teixeira, Anabela Sá, Paula Soares
DOI: 10.1016/j.rpor.2012.07.009
·
Rep Pract Oncol Radiother 2012;17(6):376-383.

open access

Vol 17, No 6 (2012)
Original research articles
Published online: 2012-11-01
Submitted: 2011-01-13

Abstract

Aim

To evaluate the differences in treatment response and the impact on survival with both oral agents (UFT and Capecitabine) as neoadjuvant chemotherapy administered concomitantly with radiotherapy.

Background

There are still no studies comparing the use of neoadjuvant oral chemotherapy either with UFT plus Folinic acid or Capecitabine concomitant with radiotherapy in locally advanced rectal cancer (LARC).

Materials and methods

A set of 112 patients with LARC were treated preoperatively. GROUP 1 – 61 patients underwent concomitant oral chemotherapy with Capecitabine (825[[ce:hsp sp="0.25"/]]mg/m2 twice daily). GROUP 2 – 51 patients submitted to concomitant oral chemotherapy with UFT (300[[ce:hsp sp="0.25"/]]mg/m2/d)[[ce:hsp sp="0.25"/]]+[[ce:hsp sp="0.25"/]]Folinic acid (90[[ce:hsp sp="0.25"/]]mg/d) and radiotherapy. 57.1% of patients were submitted to adjuvant chemotherapy.

Results

GROUP 1: acute toxicity – 80.3%; pathological complete response (pCR) – 10.5%; tumor downstaging (TD) – 49.1%; nodal downstaging (ND) – 76.5%; loco-regional response (LRR) – 71.9%; toxicity to adjuvant chemotherapy – 75%. GROUP 2: acute toxicity – 80.4%; pCR – 28%; TD – 62%; ND – 75.6%; LRR – 78%; toxicity to adjuvant chemotherapy – 56%. There was no difference in survival nor loco-regional control between the groups.

Conclusions

Patients treated with neoadjuvant oral UFT[[ce:hsp sp="0.25"/]]+[[ce:hsp sp="0.25"/]]Folinic acid had a higher rate of pathologic complete response than patients treated with Capecitabine concomitant with radiotherapy. There were no differences in downstaging, LRR, toxicity, survival or loco-regional control between both groups. There was a trend to a higher rate of toxicity to adjuvant chemotherapy in the Capecitabine group.

Abstract

Aim

To evaluate the differences in treatment response and the impact on survival with both oral agents (UFT and Capecitabine) as neoadjuvant chemotherapy administered concomitantly with radiotherapy.

Background

There are still no studies comparing the use of neoadjuvant oral chemotherapy either with UFT plus Folinic acid or Capecitabine concomitant with radiotherapy in locally advanced rectal cancer (LARC).

Materials and methods

A set of 112 patients with LARC were treated preoperatively. GROUP 1 – 61 patients underwent concomitant oral chemotherapy with Capecitabine (825[[ce:hsp sp="0.25"/]]mg/m2 twice daily). GROUP 2 – 51 patients submitted to concomitant oral chemotherapy with UFT (300[[ce:hsp sp="0.25"/]]mg/m2/d)[[ce:hsp sp="0.25"/]]+[[ce:hsp sp="0.25"/]]Folinic acid (90[[ce:hsp sp="0.25"/]]mg/d) and radiotherapy. 57.1% of patients were submitted to adjuvant chemotherapy.

Results

GROUP 1: acute toxicity – 80.3%; pathological complete response (pCR) – 10.5%; tumor downstaging (TD) – 49.1%; nodal downstaging (ND) – 76.5%; loco-regional response (LRR) – 71.9%; toxicity to adjuvant chemotherapy – 75%. GROUP 2: acute toxicity – 80.4%; pCR – 28%; TD – 62%; ND – 75.6%; LRR – 78%; toxicity to adjuvant chemotherapy – 56%. There was no difference in survival nor loco-regional control between the groups.

Conclusions

Patients treated with neoadjuvant oral UFT[[ce:hsp sp="0.25"/]]+[[ce:hsp sp="0.25"/]]Folinic acid had a higher rate of pathologic complete response than patients treated with Capecitabine concomitant with radiotherapy. There were no differences in downstaging, LRR, toxicity, survival or loco-regional control between both groups. There was a trend to a higher rate of toxicity to adjuvant chemotherapy in the Capecitabine group.

Get Citation

Keywords

Rectal cancer; Neoadjuvant oral chemoradiotherapy; Capecitabine; UFT plus Folinic acid; Pathologic complete response

About this article
Title

Comparison of neoadjuvant oral chemotherapy with UFT plus Folinic acid or Capecitabine concomitant with radiotherapy on locally advanced rectal cancer

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 17, No 6 (2012)

Pages

376-383

Published online

2012-11-01

DOI

10.1016/j.rpor.2012.07.009

Bibliographic record

Rep Pract Oncol Radiother 2012;17(6):376-383.

Keywords

Rectal cancer
Neoadjuvant oral chemoradiotherapy
Capecitabine
UFT plus Folinic acid
Pathologic complete response

Authors

Sofia Conde
Margarida Borrego
Tânia Teixeira
Rubina Teixeira
Anabela Sá
Paula Soares

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl